{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:02:36Z","timestamp":1791226956709,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,9,27]],"date-time":"2005-09-27T00:00:00Z","timestamp":1127779200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Osteosarcoma is the most common type of primary bone tumor. The use of aggressive chemotherapy has drastically improved the prognosis of the patients with non-metastatic osteosarcomas, however the prognosis of the patients with metastasis is still very poor. Then, new and more effective treatments for curing osteosarcoma, such as immunotherapy are needed. Tumor-infiltrating lymphocytes (TIL) have been involved in the control of tumor development and already assessed with success for the treatment of several cancers including melanoma. While TIL represent a fascinating therapeutic approach in numerous malignant pathologies, there is few report concerning adult bone-associated tumors including osteosarcoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Human TIL were isolated and characterized (phenotype, lytic activity) from twenty-seven patients with bone-associated tumors (osteosarcoma, Ewing's sarcoma, giant cell tumor, chondrosarcoma, plasmocytoma and bone metastases). Similar experiments were performed using rat osteosarcoma model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>While TIL with a main CD4<jats:sup>+<\/jats:sup> profile were easily isolated from most of the tumor samples, only TIL extracted from osteosarcoma were cytotoxic against allogeneic tumor cells. In all cases, TIL lytic activity was significantly higher compared to autologous peripheral blood leukocytes. Similar data were observed in rat osteosarcoma model where TIL were characterized by a main CD4<jats:sup>+<\/jats:sup> profile and high lytic activity against allogeneic and autologous tumor cells. Moreover, rat TIL expansion was not accompanied by refractoriness to further activation stimulus mainly by tumor antigens.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>These results demonstrated that TIL therapy could be a very efficient strategy for the treatment of adult osteosarcoma.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-5-123","type":"journal-article","created":{"date-parts":[[2005,9,28]],"date-time":"2005-09-28T18:14:23Z","timestamp":1127931263000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma"],"prefix":"10.1186","volume":"5","author":[{"given":"S","family":"Th\u00e9oleyre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Cherrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Passuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Gouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"R\u00e9dini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Heymann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,9,27]]},"reference":[{"key":"311_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/1097-0142(197601)37:1<1::AID-CNCR2820370102>3.0.CO;2-3","volume":"37","author":"G Rosen","year":"1976","unstructured":"Rosen G, Murphy ML, Huvos AG, Gutierrez M, Marcove RC: Chemotherapy, en bloc resection, and prosthetic bone replacement in treatment of osteogenic sarcoma. Cancer. 1976, 37: 1-11.","journal-title":"Cancer"},{"key":"311_CR2","first-page":"8","volume":"270","author":"MP Link","year":"1991","unstructured":"Link MP, Goorin AM, Horowitz M, Meyer WH, Belasco J, Baker A, Ayala A, Shuster J: Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the multi-institutional osteosarcoma study. Clin Orthop. 1991, 270: 8-14.","journal-title":"Clin Orthop"},{"key":"311_CR3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.1997.15.1.76","volume":"15","author":"AJ Provisor","year":"1997","unstructured":"Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ, Huvos AG, Betcher DL, Baum ES, Kisker CT, Miser JS: Treatment of non-metastatic osteosarcoma of the extremity with pre-operative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol. 1997, 15: 76-84.","journal-title":"J Clin Oncol"},{"key":"311_CR4","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.3489291","volume":"233","author":"SA Rosenberg","year":"1986","unstructured":"Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986, 233: 1318-1321.","journal-title":"Science"},{"key":"311_CR5","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1093\/jnci\/83.13.932","volume":"83","author":"P Aebersold","year":"1991","unstructured":"Aebersold P, Hyatt C, Johnson S, Hines K, Korcak L, Sanders M, Lotze M, Topalian S, Yang J, Rosenberg SA: Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. J Natl Cancer Inst. 1991, 83: 932-937.","journal-title":"J Natl Cancer Inst"},{"key":"311_CR6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/35077246","volume":"411","author":"SA Rosenberg","year":"2001","unstructured":"Rosenberg SA: Progress in human tumour immunology and immunotherapy. Nature. 2001, 411: 380-384. 10.1038\/35077246.","journal-title":"Nature"},{"key":"311_CR7","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/00002371-200307000-00005","volume":"26","author":"ME Dudley","year":"2003","unstructured":"Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA: Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003, 26: 332-342. 10.1097\/00002371-200307000-00005.","journal-title":"J Immunother"},{"key":"311_CR8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/030089160008600109","volume":"86","author":"M Fabbri","year":"2000","unstructured":"Fabbri M, Ridolfi R, Maltino R, Ridolfi L, Riccobon A, Flamini E, De Paola F, Verdecchia GM, Amadori D: Tumor infiltrating lymphocytes and continous infusion interleukin-2 after metastasectomy in 61 patients with melanoma, colorectal and renal carcinoma. Tumori. 2000, 86: 46-52.","journal-title":"Tumori"},{"key":"311_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/01.cji.0000158855.92792.7a","volume":"28","author":"J Huang","year":"2005","unstructured":"Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA, Robbins PF: Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother. 2005, 28: 258-267. 10.1097\/01.cji.0000158855.92792.7a.","journal-title":"J Immunother"},{"key":"311_CR10","first-page":"763","volume":"14","author":"F El Hage","year":"2005","unstructured":"El Hage F, Vergnon I, Grunenwald D, Soria JC, Chouaib S, Mami-Chouaib F: Generation of diverse mutated tumor antigen-specific cytotoxic T lymphocytes in a lung cancer patient with long survival. Oncol Rep. 2005, 14: 763-769.","journal-title":"Oncol Rep"},{"key":"311_CR11","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1089\/cbr.2004.19.730","volume":"19","author":"R Dillma","year":"2004","unstructured":"Dillma R, Schiltz P, DePriest C, Barth N, Beutel L, de Leon C, O'Connor A, Nayak S: Tumor-infiltrating lymphocytes and interleukin-2: dose and schedules of administration in the treatment of metastatic cancer. Cancer Biother Radiopharm. 2004, 19: 730-737. 10.1089\/cbr.2004.19.730.","journal-title":"Cancer Biother Radiopharm"},{"key":"311_CR12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1046\/j.1464-410X.1997.00408.x","volume":"80","author":"D Kowalczyk","year":"1997","unstructured":"Kowalczyk D, Skorupski W, Kwias Z, Nowak J: Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma. Br J Urol. 1997, 80: 543-547.","journal-title":"Br J Urol"},{"key":"311_CR13","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0959-8049(99)00033-7","volume":"35","author":"AC Dierderichsen","year":"1999","unstructured":"Dierderichsen AC, Zeuthen J, Christensen PB, Kristensen T: Characterization of tumour infiltrating lymphocytes and correlations with immunological surface molecules in colorectal cancer. Eur J Cancer. 1999, 35: 721-726. 10.1016\/S0959-8049(99)00033-7.","journal-title":"Eur J Cancer"},{"key":"311_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejso.2003.10.001","volume":"30","author":"M Ikeguchi","year":"2004","unstructured":"Ikeguchi M, Oi K, Hirooka Y, Kaibara N: CD8+ lymphocyte infiltration and apoptosis in hepatocellular carcinoma. Eur J Surg Oncol. 2004, 30: 53-57. 10.1016\/j.ejso.2003.10.001.","journal-title":"Eur J Surg Oncol"},{"key":"311_CR15","first-page":"1050","volume":"12","author":"E Yakirevich","year":"1999","unstructured":"Yakirevich E, Izhak OB, Rennert G, Kovacs ZG, Resnick MB: Cytotoxic phenotype of tumor infiltrating lymphocytes in medullary carcinoma of the breast. Mod Pathol. 1999, 12: 1050-1056.","journal-title":"Mod Pathol"},{"key":"311_CR16","doi-asserted-by":"publisher","first-page":"14565","DOI":"10.1073\/pnas.251140998","volume":"98","author":"M Mercader","year":"2001","unstructured":"Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, Ellis TM, Wojcik EM, Yang D, Flanigan RC, Waters WB, Kast WM, Kwon ED: T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA. 2001, 98: 14565-14570. 10.1073\/pnas.251140998.","journal-title":"Proc Natl Acad Sci USA"},{"key":"311_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2169\/internalmedicine.43.323","volume":"43","author":"M Kobayashi","year":"2004","unstructured":"Kobayashi M, Ito M, Sano K, Honda T, Nakayama J: Pulmonary lymphoepithelioma-like carcinoma: predominant infiltration of tumor-associated cytotoxic T lymphocytes might represent the enhanced tumor immunity. Intern Med. 2004, 43: 323-326. 10.2169\/internalmedicine.43.323.","journal-title":"Intern Med"},{"key":"311_CR18","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1158\/0008-5472.CAN-04-3337","volume":"65","author":"K Noonan","year":"2005","unstructured":"Noonan K, Matsui W, Serafini P, Carbley R, Tan G, Khalifi J, Bonyhadi M, Levitsky H, Whartenby K, Borrelo I: Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res. 2005, 65: 2026-2034. 10.1158\/0008-5472.CAN-04-3337.","journal-title":"Cancer Res"},{"key":"311_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/BF01741792","volume":"34","author":"L Rivoltini","year":"1992","unstructured":"Rivoltini L, Arienti F, Orazi A, Cefalo G, Gasparini M, Gambacorti-Passerini C, Fossati-Bellani F, Parmiani G: Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype. Cancer Immunol Immunother. 1992, 34: 241-251. 10.1007\/BF01741792.","journal-title":"Cancer Immunol Immunother"},{"key":"311_CR20","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S0002-9440(10)61772-5","volume":"159","author":"C Zietz","year":"2001","unstructured":"Zietz C, Rumpler U, Sturzl M, Lohrs U: Inverse relation of Fas-ligand and tumor-infiltrating lymphocytes in angiosarcoma: indications of apoptotic tumor counterattack. Am J Pathol. 2001, 159: 963-970.","journal-title":"Am J Pathol"},{"key":"311_CR21","first-page":"1137","volume":"19","author":"MR Barber","year":"1999","unstructured":"Barber MR, Yang TJ: Tumor infiltrating lymphocytes: CD8+ lymphocytes in canine transmissible venereal sarcomas at different stages of tumor growth. Anticancer Res. 1999, 19: 1137-1142.","journal-title":"Anticancer Res"},{"key":"311_CR22","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1002\/eji.200425866","volume":"35","author":"R Yu","year":"2005","unstructured":"Yu R, Fujio K, Tahara H, Araki Y, Yamamoto K: Clonal dynamics of tumor-infiltrating lymphocytes. Eur J Immunol. 2005, 35: 1754-1763. 10.1002\/eji.200425866.","journal-title":"Eur J Immunol"},{"key":"311_CR23","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","volume":"86","author":"SA Rosenberg","year":"1994","unstructured":"Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994, 86: 1159-1166.","journal-title":"J Natl Cancer Inst"},{"key":"311_CR24","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00262-002-0315-1","volume":"51","author":"B Dreno","year":"2002","unstructured":"Dreno B, Nguyen JM, Khammari A, Pandolfino MC, Tessier MH, Bercegeay S, Cassidanius A, Lemarre P, Billaudel S, Labarriere N, Jotereau F: Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother. 2002, 51: 539-546. 10.1007\/s00262-002-0315-1.","journal-title":"Cancer Immunol Immunother"},{"key":"311_CR25","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/BF02306093","volume":"3","author":"UL Burger","year":"1996","unstructured":"Burger UL, Chang MP, Nagoshi M, Goedegebuure PS, Eberlein TJ: Improved in vivo efficacy of TIL after restimulation with irradiated tumor cells in vitro. Ann Surg Oncol. 1996, 3: 580-587.","journal-title":"Ann Surg Oncol"},{"key":"311_CR26","first-page":"332","volume":"38","author":"M Harada","year":"1994","unstructured":"Harada M, Matsuzaki G, Shinomiya Y, Kurosawa S, Ito O, Okamoto T, Takenoyama M, Sumitika H, Nishimura Y, Nomoto K: Generation of tumor-specific cytotoxic T lymphocytes in vivo combined treatment with inactivated tumor cells and recombinant interleukin-2. Cancer Immunol Immunother. 1994, 38: 332-338.","journal-title":"Cancer Immunol Immunother"},{"key":"311_CR27","first-page":"149","volume":"9","author":"JC Yang","year":"1990","unstructured":"Yang JC, Perry-Lalley D, Rosenberg SA: An improved method for growing murine tumor-infiltrating lymphocytes with in vivo antitumor activity. J Biol Response Mod. 1990, 9: 149-159.","journal-title":"J Biol Response Mod"},{"key":"311_CR28","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.3489291","volume":"233","author":"SA Rosenberg","year":"1986","unstructured":"Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with infiltrating lymphocytes. Science. 1986, 233: 1318-1321.","journal-title":"Science"},{"key":"311_CR29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/ijc.2910200118","volume":"20","author":"B Klein","year":"1977","unstructured":"Klein B, Pals S, Masse R, Lafuma J, Morin M, Binart N, Jasmin JR, Jasmin C: Studies of bone and soft-tissue tumours induced in rats with radioactive cerium chloride. Int J Cancer. 1977, 20: 112-119.","journal-title":"Int J Cancer"},{"key":"311_CR30","first-page":"1686","volume":"58","author":"J-P Thi\u00e9ry","year":"1982","unstructured":"Thi\u00e9ry J-P, Perdereau B, Gongora R, Gongora G, Mazabraud A: Un mod\u00e8le experimental d'ost\u00e9osarcome chez le rat. II L'ost\u00e9osarcome greffable du rat. Sem H\u00f4p Paris. 1982, 58: 1686-1689.","journal-title":"Sem H\u00f4p Paris"},{"key":"311_CR31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.bone.2005.02.020","volume":"37","author":"D Heymann","year":"2005","unstructured":"Heymann D, Ory B, Blanchard F, Heymann MF, Coipeau P, Charrier C, Couillaud S, Thi\u00e9ry JP, Gouin F, R\u00e9dini F: Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone. 2005, 37: 74-86. 10.1016\/j.bone.2005.02.020.","journal-title":"Bone"},{"key":"311_CR32","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/eji.1830210612","volume":"21","author":"DH Lynch","year":"1991","unstructured":"Lynch DH, Miller RE: Immunotherapeutic elimination of syngenic tumors in vivo by cytotoxic T lymphocytes generated in vitro from lymphocytes from the draining lymph nodes of tumor-bearing mice. Eur J Immunol. 1991, 21: 1403-1410.","journal-title":"Eur J Immunol"},{"key":"311_CR33","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1600-065X.1995.tb00081.x","volume":"145","author":"CJ Melief","year":"1995","unstructured":"Melief CJ, Kast WM: T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev. 1995, 145: 167-177.","journal-title":"Immunol Rev"},{"key":"311_CR34","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/BF01741792","volume":"34","author":"L Rivoltini","year":"1992","unstructured":"Rivoltini L, Arienti F, Orazi A, Cefalo G, Gasparini M, Gambacorti-Passerini C, Fossati-Bellani F, Parmiani G: Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype. Cancer Immunol Immunother. 1992, 34: 241-251. 10.1007\/BF01741792.","journal-title":"Cancer Immunol Immunother"},{"key":"311_CR35","unstructured":"Haanen JB, Baars A, Gomez R, Weber P, Smits M, de Gruijl TD, von Blomberg BM, Bloemena E, Scheper RJ, van Ham SM, Pinedo HM, van den Eertwegh AJ: Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother."},{"key":"311_CR36","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0344-0338(98)80126-X","volume":"194","author":"K Trieb","year":"1998","unstructured":"Trieb K, Lechleitner T, Lang S, Windhager R, Kotz R, Dirnhofer S: Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma. Pathol Res Pract. 1998, 194: 679-684.","journal-title":"Pathol Res Pract"},{"key":"311_CR37","first-page":"390","volume":"37","author":"SL Topalian","year":"1987","unstructured":"Topalian SL, Muul LM, Rosenberg SA: Growth and immunological characteristics of lymphocytes infiltrating human tumors [abstract]. Surg Forum. 1987, 37: 390-","journal-title":"Surg Forum"},{"key":"311_CR38","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.4049\/jimmunol.174.5.2591","volume":"174","author":"PA Antony","year":"2005","unstructured":"Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, Palmer DC, Chan CC, Klebanoff CA, Overwijk WW, Rosenberg SA, Resifo NP: CD8+ T cell immunity against a tumor\/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005, 174: 2591-601.","journal-title":"J Immunol"},{"key":"311_CR39","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1084\/jem.20041684","volume":"201","author":"P Yu","year":"2005","unstructured":"Yu P, Lee Y, Liu W, Krusz T, Chong A, Schreiber H, Fu YX: Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med. 2005, 201: 779-791. 10.1084\/jem.20041684.","journal-title":"J Exp Med"},{"key":"311_CR40","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-04-3232","volume":"65","author":"LA Ormandy","year":"2005","unstructured":"Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 2005, 65: 2457-2464. 10.1158\/0008-5472.CAN-04-3232.","journal-title":"Cancer Res"},{"key":"311_CR41","doi-asserted-by":"publisher","first-page":"5959","DOI":"10.4049\/jimmunol.174.10.5959","volume":"174","author":"H Kojima","year":"2005","unstructured":"Kojima H, Kanno Y, Hase H, Kobata T: CD4+CD25+ regulatory T cells attenuate the phosphatidylinositol 3-kinase\/Akt pathway in antigen-primed immature CD8+ CTLs during functional maturation. J Immunol. 2005, 174: 5959-5967.","journal-title":"J Immunol"},{"key":"311_CR42","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1158\/0008-5472.CAN-04-3104","volume":"65","author":"SE Erman","year":"2005","unstructured":"Erman SE, Sohn JJ, Rao VP, Nambiar PR, Ge Z, Fox JG, Schauer DB: CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin\/+ mice. Cancer Res. 2005, 65: 3998-4004. 10.1158\/0008-5472.CAN-04-3104.","journal-title":"Cancer Res"},{"key":"311_CR43","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/jor.1100150119","volume":"15","author":"T Sudo","year":"1997","unstructured":"Sudo T, Kuramoto T, Komiya S, Inoue A, Itoh K: Expression of MAGE genes in osteosarcoma. J Orthop Res. 1997, 15: 128-132. 10.1002\/jor.1100150119.","journal-title":"J Orthop Res"},{"key":"311_CR44","first-page":"29","volume":"17","author":"H Ishida","year":"2000","unstructured":"Ishida H, Komiya S, Inoue Y, Yutani S, Inoue A, Itoh K: Expression of the SART1 tumor-rejection antigen in human osteosarcomas. Int J Oncol. 2000, 17: 29-32.","journal-title":"Int J Oncol"},{"key":"311_CR45","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S0736-0266(00)90031-7","volume":"19","author":"N Tsuda","year":"2001","unstructured":"Tsuda N, Murayama K, Ishida H, Matsunaga K, Komiya S, Itoh K, Yamada A: Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides. J Orthop Res. 2001, 19: 346-351. 10.1016\/S0736-0266(00)90031-7.","journal-title":"J Orthop Res"},{"key":"311_CR46","doi-asserted-by":"publisher","first-page":"5442","DOI":"10.1158\/0008-5472.CAN-04-0522","volume":"64","author":"T Tsukahara","year":"2004","unstructured":"Tsukahara T, Nabeta Y, Kawaguchi S, Ikeda H, Sato Y, Shimozawa K, Ida K, Asanuma H, Hirohashi Y, Torigoe T, Hiraga H, Nagoya S, Wada T, Yamashita T, Sato N: Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor. Cancer Res. 2004, 64: 5442-5448. 10.1158\/0008-5472.CAN-04-0522.","journal-title":"Cancer Res"},{"key":"311_CR47","first-page":"3950","volume":"7","author":"Y Miyagi","year":"2001","unstructured":"Miyagi Y, Imai N, Sasatomi T, Yamada A, Mine T, Katagiri K, Nakagawa M, Muto A, Okouchi S, Isomoto H, Shirouzu K, Yamana H, Itoh K: Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res. 2001, 7: 3950-3962.","journal-title":"Clin Cancer Res"},{"key":"311_CR48","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/08880010050034283","volume":"17","author":"K Trieb","year":"2000","unstructured":"Trieb K, Lang S, Kotz R: Heat-shock protein 72 in human osteosarcoma: T-lymphocytes reactivity and cytotoxicity. Pediatr Hematol Oncol. 2000, 17: 355-364. 10.1080\/08880010050034283.","journal-title":"Pediatr Hematol Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-5-123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-5-123\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-5-123","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-5-123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T21:48:06Z","timestamp":1630446486000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-5-123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,27]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["311"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-5-123","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,27]]},"assertion":[{"value":"6 June 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"123"}}